| Literature DB >> 23319908 |
Abstract
Our case describes clinical features of two families defined by joint phenotypes: sodium oxybate intolerance and elevated serum acylcarnitines. Oxybate intolerance variably presents as either cervical dystonia or sleep-related eating disorder. Our objective is to identify biological markers which predict a poor response to sodium oxybate as a treatment for disturbed sleep. Familial inheritance pattern, genotype analysis, multiorgan system involvement, and response to treatment suggest the presence of a secondary cause of fatty oxidation defect, i.e., mitochondrial disorder. Our case report supports the possible conclusion that variance in human mitochondrial metabolism may affect sodium oxybate tolerability.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23319908 PMCID: PMC3525992 DOI: 10.5664/jcsm.2346
Source DB: PubMed Journal: J Clin Sleep Med ISSN: 1550-9389 Impact factor: 4.062